Acrivon Therapeutics Inc.
Organization details
- Legal name
- Acrivon Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Headquarters city
- Watertown
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ACRV
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001781174
- EIN
- 82-5125532
Board of directors
-
Charles M. Baum · DirectorSince 2023
-
Derek DiRocco · DirectorSince 2024
-
Ivana Magovcevic-Liebisch · DirectorSince 2024
-
Kristina Masson · Director · EVP - Business OperationsSince 2023
-
Michael John Tomsicek · DirectorSince 2024
-
Peter Blume-Jensen · Director · President and CEOSince 2023
- Since 2024
- Since 2024
-
Santhosh Palani · DirectorSince 2024
-
Sharon Shacham · DirectorSince 2024
Chief executives
Director election results
Annual meeting of June 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
93.7%
-
95.1%
Board connections
8 of this board's directors also sit on 31 other boards. 30 are in the same sector.
-
Evommune Inc. Same sectorvia Derek DiRocco, Peter Kolchinsky and Rajeev M. Shah
-
Mineralys Therapeutics Inc. Same sectorvia Derek DiRocco, Peter Kolchinsky and Rajeev M. Shah
-
Werewolf Therapeutics Inc. Same sectorvia Derek DiRocco, Peter Kolchinsky and Rajeev M. Shah
-
ARS Pharmaceuticals Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Acumen Pharmaceuticals Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Artiva Biotherapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Bambusa Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Bicara Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Black Diamond Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Climb Bio Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Freenome Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Hemab Therapeutics Holdings Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Jade Biosciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Janux Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
LENZ Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Nkarta Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Parabilis Medicines Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
PepGen Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Septerna Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Sionna Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Solid Biosciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
SpyGlass Pharma Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Tyra Biosciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Vor Biopharma Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Wave Life Sciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Milestone Pharmaceuticals Inc. Same sectorvia Michael John Tomsicek
-
Nasus Pharma Ltd. Same sectorvia Sharon Shacham
-
PMV Pharmaceuticals Inc. Same sectorvia Charles M. Baum
-
Pyxis Oncology Inc. Same sectorvia Santhosh Palani
- via Ivana Magovcevic-Liebisch
-
Spyre Therapeutics Inc. Same sectorvia Ivana Magovcevic-Liebisch
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $114,534
- 3 purchases by 3 insiders
- Sold, last 12 months
- $41,386
- 11 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 22, 2026 | Miller Mary Officer (Chief Legal Officer) | Open-market sale | −513 | $1.84 | $944 |
| Oct 5, 2026 | Miller Mary Officer (Chief Legal Officer) | Open-market sale | −294 | $1.99 | $585 |
| Aug 31, 2026 | Levin Michaela Officer (Chief Business Officer) | Grant or award | +30,000 | — | — |
| Aug 25, 2026 | Peter Blume-Jensen Director, Officer (President and CEO) | Open-market sale | −14,036 | $2.21 | $31,020 |
| Aug 18, 2026 | Kristina Masson Director, Officer (EVP - Business Operations) | Open-market sale | −1,229 | $2.01 | $2,470 |
| Aug 18, 2026 | Devroe Eric Officer (Chief Operating Officer) | Open-market sale | −604 | $2.01 | $1,214 |
| Aug 18, 2026 | Gamelin Erick Officer (Chief Development Officer) | Open-market sale | −400 | $2.01 | $804 |
| Aug 18, 2026 | Miller Mary Officer (Chief Legal Officer) | Open-market sale | −185 | $2.01 | $372 |
| Aug 18, 2026 | Peterson Katharine Officer (Chief Accounting Officer) | Open-market sale | −101 | $2.01 | $203 |
| Aug 18, 2026 | Kristina Masson Director, Officer (EVP - Business Operations) | Open-market sale | −484 | $2.01 | $973 |
| Aug 4, 2026 | Levy Adam D. Officer (Chief Financial Officer) | Open-market sale | −1,142 | $1.57 | $1,793 |
| Jul 21, 2026 | Miller Mary Officer (Chief Legal Officer) | Open-market sale | −573 | $1.76 | $1,008 |
| May 21, 2026 | Kristina Masson Director, Officer (EVP - Business Operations) | Shares withheld for tax | −13,729 | $1.79 | $24,575 |
| May 18, 2026 | RA Capital Nexus Fund II, L.P. Director | Grant or award | +9,366 | — | — |
| May 18, 2026 | Michael John Tomsicek Director | Grant or award | +9,366 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Acrivon Therapeutics Inc.
Who is the CEO of Acrivon Therapeutics Inc.?
Peter Blume-Jensen is Acrivon Therapeutics Inc.'s President and CEO.
How many directors are on Acrivon Therapeutics Inc.'s board?
Acrivon Therapeutics Inc.'s board has 10 directors: Charles M. Baum, Derek DiRocco, Ivana Magovcevic-Liebisch, Kristina Masson, Michael John Tomsicek, Peter Blume-Jensen, Peter Kolchinsky, Rajeev M. Shah, Santhosh Palani and Sharon Shacham.
Are Acrivon Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Acrivon Therapeutics Inc. insiders bought $114,534 of shares in 3 purchases and sold $41,386 of shares in 11 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="acrivon-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.